Personathersp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Personather, founded in 2015, develops anticancer therapies and diagnostic tools based on personalized medicine, targeting cancer cells. The company also provides biotechnology services and conducts its own preclinical projects; its team works in fields including bioinformatics, molecular and cellular biology, and genetic engineering.
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 54 days late).
- 202502/07/2026
- 202404/07/2025
- 202309/07/2024
- 202212/07/2023
- 202107/09/2022
- 202022/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
Each member of the management board is authorised to make declarations of will on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Sylwester Jakub Piaskowskiage 51 | 10 | $135.06 | 10% |
Piotr Rieskeage 55 | 10 | $135.06 | 10% |
Ewelina Anna Stoczyńska Fidelusage 41 | 10 | $135.06 | 10% |
Wioletta Jadwiga Zdańskaage 47 | 70 | $945.43 | 70% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-07-01.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-01-01 | Development of targeted anticancer therapy based on small-molecule compounds regulating the mutated RAS G12V protein. | $982.3K$982,323 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Awtmsp. z o.o. | $123,062.45 | awtm.pl | ||
| New Valuesp. z o.o. | $64,335.86 | new-value.pl | ||
| Oncocdxsp. z o.o. | $58,823.32 | oncocdx.org | ||
| Fly-Gensp. z o.o. | $45,325.87 | fly-gen.pl | ||
| VB IdeaP.S.A. | $44,631.63 | vbidea.pl | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| Cellissp. z o.o. | $24,935.59 | cellis.eu | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Neuro-Opiomelsp. z o.o. | $19,173.50 | neuroopiomel.com |
Change history
| Date | Event | |
|---|---|---|
| 2016-01-28 | PKD change (Added: 9 codes) | |
| 2015-09-24 | Entered in the register |
FAQ
Last updated: 2026-09-29